Bristol Myers Squibb has agreed to buy RayzeBio for approximately $4.1 billion, marking its second major acquisition in three days. The deal will enhance Bristol Myers' oncology portfolio with RayzeBio's radiopharmaceutical platform, which uses targeted doses of radiation for cancer treatment. RayzeBio's stock soared following the announcement, reflecting a 98.4% premarket surge. Shareholders of RayzeBio are set to receive $62.50 per share in cash as part of the acquisition.
Bristol Myers will pay $4.1 billion for cancer startup RayzeBio, with a pipeline of radiopharmaceuticals that pair the tumor-killing power of radiation with the precision of targeted cancer therapies. https://t.co/TUI0JCK5q8 via @statnews
Bristol Myers Squibb has agreed to buy cancer therapy company RayzeBio for an equity value of about $4.1 billion. https://t.co/8C5TtrH0Mn
Bristol Myers Squibb will pay $4.1 billion for RayzeBio, buying into the fast-growing field of using targeted doses of radiation to treat cancer. https://t.co/ohd6A5l6fQ
RayzeBio soars; Bristol Myers to pay $4.1 billion in second major buy in 3 days https://t.co/T20UJWmAOv
$RYZB (+98.4% pre) $BMY Bristol Myers Squibb acquires Rayzebio for $4.1B, adds radiopharmaceutical platform to oncology portfolio ($62.50/sh cash) - SA https://t.co/U0VIhyyMV8
Bristol Myers Squibb agrees to buy radiological drug developer RayzeBio for about $4.1 billion, the latest deal in a buying spree to bolster its pipeline https://t.co/IAHzG2FgK7
Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion https://t.co/DF4kTHe1UJ
Bristol Myers to buy RayzeBio for about $4.1 billion https://t.co/TY8IP9z1nC https://t.co/4ahjARqRyl
$RYZB RayzeBio to be acquired by Bristol Myers Squibb for $62.50/sh, or $4.1bn $BMS https://t.co/D3xXHLGXYr